Geneos Therapeutics develops personalized therapeutic cancer vaccines (PTCVs) using its proprietary GT-EPIC™ platform, which customizes DNA plasmids to encode up to 40 unique neoantigens from a patient's tumor. This approach aims to enhance the immune response against cancer by generating tumor-infiltrating lymphocytes that target and potentially eradicate cancer cells throughout the body.
Funding
$49.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SHFounders
Product
Problem
Current cancer treatments often fail to eradicate tumors completely, leading to recurrence and metastasis. Traditional approaches may not effectively target the unique mutations present in each patient's tumor, limiting the immune system's ability to recognize and destroy cancer cells.
Solution
Geneos Therapeutics develops personalized therapeutic cancer vaccines (PTCVs) designed to stimulate a targeted immune response against a patient's specific tumor neoantigens. The company's GT-EPIC™ platform creates customized DNA plasmids encoding up to 40 neoantigens derived from an individual's tumor. These PTCVs are administered intradermally with a cytokine adjuvant and electroporation to enhance DNA plasmid uptake. This process directs the immune system to generate tumor-infiltrating lymphocytes (TILs) that are programmed to recognize and eliminate cancer cells throughout the body. The approach aims to leverage the patient's own immune system to reduce or eradicate the cancer by targeting the unique neoantigens expressed by their tumor.
Target Audience
The primary target audience includes oncology researchers and clinicians focused on developing personalized immunotherapies for cancer patients, particularly those with solid tumors expressing neoantigens.
Features
- GT-EPIC™ platform for identifying and encoding up to 40 unique neoantigens per patient
- Personalized DNA plasmids designed to drive a tumor-targeted, neoantigen-specific immune response
- Plasmid-encoded IL-12 (pIL12) intradermal adjuvant to drive a Th1 response to vaccine-encoded antigens, remaining localized to the skin
- CELLECTRA® in vivo intradermal electroporation device to enhance cellular uptake of the DNA plasmid at the injection site
- Induction of new and expanded CD8 T-effector memory cells with cytotoxic phenotype